Observational Study
Copyright ©The Author(s) 2024.
World J Radiol. Jun 28, 2024; 16(6): 221-231
Published online Jun 28, 2024. doi: 10.4329/wjr.v16.i6.221
Table 1 Baseline clinical characteristics of the study population, n = 200
Parameter
Frequency
Age in yr, mean ± SD49.08 ± 11.68
Male, n (%)159 (79.5)
Etiology of cirrhosis, n (%)
Alcohol78 (39.0)
NAFLD49 (24.5)
Viral 37 (18.5)
Others36 (18.0)
CTP Class, n (%)
A23 (11.5)
B66 (33.0)
C111 (55.5)
Cirrhosis duration in mo, median (IQR)6.00 (2.001-4.40)
CTP score, mean ± SD9.59 ± 2.27
MELD-Na score, median21 (7-40) ± 7.19
BMI, mean ± SD19.79 ± 3.05
Comorbidity, n (%)
None121 (60.5)
Type 2 DM34 (17.0)
HTN44 (22.0)
Hypothyroidism1 (0.5)
Duration of type 2 DM in mo, mean ± SD23.94 ± 13.3
Duration of HTN in mo, mean ± SD24.09 ± 11.84
ACLF presence, n (%)27 (13.5)
ACLF grade among n = 27, n (%)
I6 (22.2)
II10 (37.0)
III11 (40.7)
Abdominal circumference in cm, mean ± SD95.64 ± 16.28
Ascites among n = 153, n (%)
Grade II 70 (45.7)
Grade III83 (54.3)
Diuretic responsive90 (59.0)
Diuretic resistant63 (41.0)
MAP in mmHg, mean ± SD76.16 ± 5.39
Heart rate in bpm, median (IQR)80.00 (60.00-130.00)
Table 2 Baseline clinical characteristics according to the type of acute kidney injury, n = 200
Parameter
PRA, n = 29
ATN-AKI, n = 18
HRS-AKI, n = 82
No-AKI, n = 71
aP value
Age in yr, mean ± SD53.9 ± 10.143.3 ± 10.850.7 ± 11.346.8 ± 12.00.003
Sex as male/female26/316/264/1853/180.268
Etiology of cirrhosis: Alcohol/NAFLD/viral/others15/9/4/114/1/2/125/21/25/1124/18/17/120.012
Hepatic encephalopathy, n (%)4 (13.7)1 (5.5)5 (6.1)7 (9.8)0.568
GI bleed, n (%)1 (3.4)0 (0.0)2 (2.4)55 (69.6)< 0.001
Sepsis, n (%) 2 (6.9)12 (66.6)49 (59.7)0 (0.0)< 0.001
Shock, n (%)0 (0.0)18 (100.0)0 (0.0)0 (0.0)< 0.001
ACLF, n (%)0 (0.0)13 (72.2)14 (17.0)0 (0.0)< 0.001
CTP score, mean ± SD9.83 ± 1.6111.89 ± 1.0810.44 ± 1.877.93 ± 2.08< 0.001
MELD-Na score, mean ± SD21.50 ± 5.54 29.60 ± 7.1922.10 ± 7.10 17.70 ± 5.70< 0.001
Stage of AKI: Stage 1/stage 2/stage 316/13/03/5/1032/29/210/0/0< 0.001
Ascites: No/diuretic responsive/refractory1/26/20/7/110/34/4846/23/2< 0.001
Hemoglobin in g/dL, mean ± SD7.78 ± 1.588.79 ± 2.278.87 ± 1.757.97 ± 2.540.010
Total leukocyte count as cells/mm3, mean ± SD7410 ± 575013760 ± 67607290 ± 39905640 ± 3290< 0.001
Platelet count as cells/mm3, mean ± SD89700 ± 3160097100 ± 2760098000 ± 3270098200 ± 384000.654
Bilirubin in mg/dL, mean ± SD1.76 ± 1.1310.11 ± 8.703.62 ± 3.352.20 ± 1.82< 0.001
ALT in U/L, mean ± SD40.5 ± 23.153.1 ± 24.657.1 ± 77.938.6 ± 28.90.078
AST in U/L, mean ± SD64.3 ± 41.2130.7 ± 59.1109.4 ± 63.268.4 ± 66.9< 0.001
INR, mean ± SD1.64 ± 0.422.43 ± 0.661.83 ± 0.571.57 ± 0.45< 0.001
Albumin, mean ± SD2.80 ± 0.412.48 ± 0.342.62 ± 0.432.98 ± 0.47< 0.001
Urea in mg/dL, mean ± SD90.10 ± 20.2433.40 ± 6.8544.3 ± 29.6844.0 ± 26.31< 0.001
Creatinine in mg/dL on Day 1, mean ± SD1.68 ± 0.1910.911 ± 0.2641.335 ± 0.7780.940 ± 0.276< 0.001
Creatinine in mg/dL on Day 3, mean ± SD1.53 ± 0.3153.10 ± 1.1652.81 ± 1.5370.975 ± 0.212< 0.001
CRP in mg/L, mean ± SD38.6 ± 28.142.2 ± 25.737.7 ± 32.723.4 ± 19.9< 0.001
Serum sodium in mEq/L, mean ± SD126 ± 23.52128 ± 6.26130 ± 6.66133 ± 4.890.001
Serum potassium in mEq/L, mean ± SD4.42 ± 0.6114.35 ± 0.6044.25 ± 0.6684.14 ± 0.5520.155
RRI, mean ± SD0.63 ± 0.070.80 ± 0.020.73 ± 0.00.60 ± 0.07< 0.001
Table 3 Comparison of clinical parameters in patients with and without high RRI, n = 200
Parameters
High RRI, > 0.73,
n = 82
Low RRI, ≤ 0.73,
n = 118
aP value
Age in yr, mean ± SD47.98 ± 11.0150.40 ± 12.370.810
Sex
Male, n (%)69 (84.1)90 (76.2)0.170
Comorbidity, n (%)
Present 19 (23.2)60 (50.8) 0.110
ACLF among n = 2720 (24.3)7 (5.9)< 0.001
ACLF grade, n (%)
Grade I5 (25)1 (0.8)0.002
Grade II7 (35)3 (2.5)
Grade III8 (40)3 (2.5)
AKI, n (%)79 (96.3)50 (42.4)< 0.001
AKI stage among n = 129, n (%)
Stage I27 (32.9)24 (20.3)
Stage II28 (34.1) 19 (16.1)
Stage III24 (29.2)7.0 (5.9)
AKI phenotype among n = 129, n (%)
ATN-AKI 17 (94.4)1 (0.8)< 0.001
HRS-AKI59 (72)23 (19.4)
PRA3 (10.3)26 (22.0)
BMI in kg/m²19.70 ± 3.0619.87 ± 3.060.169
Abdominal circumference in cm102.98 ± 10.2 90.54 ± 17.6< 0.001
Duration of cirrhosis in mo10.96 ± 11.510.55 ± 12.180.574
Etiology, n (%)
Alcohol31 (37.8)47 (39.8)0.907
NAFLD19 (23.2)30 (25.4)
Viral22 (26.8)15 (12.7)
Others10 (12.2)26 (22.1)
CTP class, n (%)
A1 (1.2)22 (18.6)< 0.001
B17 (20.7)49 (41.5)
C64 (78.1)47 (39.8)
MELD-Na Score23 (7-33)19 (7-28)< 0.001
Ascites among n = 153, n (%)
Grade-II 26 (32.5) 44 (37.2.3)< 0.001
Grade-III54 (67.5)29 (24.5)
MAP in mmHg73.50 ± 6.7778.2 ± 2.61< 0.001
Heart rate 90.8 ± 16.5580.8 ± 7.35< 0.001
Table 4 Discriminatory performance of renal resistive index for different phenotypes of acute kidney injury
Parameters
AUROC curve
RRI cut-off
Sensitivity
Specificity
PPV
NPV
ATN-AKI vs non-ATN AKI94%0.7789%96%80%98%
ATN-AKI vs HRS-AKI94%0.7789%98%94%97%
ATN-AKI vs PRA93%0.73100%89%85%100%
HRS-AKI vs non HRS-AKI56%0.7294%55%78%84%
HRS-AKI vs PRA87%0.7195%89%96%86%
PRA vs no-AKI59%0.5976%45%36%81%